USP <467> Residual Solvents Testing: What the Updated Standard Means for Supplement Manufacturers

The supplement sitting in your warehouse might have passed potency testing, cleared heavy metals, and come back clean on microbials. And it might still be shipping with hexane levels above USP <467> limits. We see it with enough regularity that it’s stopped surprising us — but it never stops being a problem for the brands on the receiving end.

Residual solvent testing is the compliance gap that doesn’t make headlines until something goes wrong. It lacks the urgency of a Salmonella recall or a lead contamination crisis, so it gets deprioritized. But with FDA intensifying scrutiny on supplement ingredient sourcing and USP’s updated analytical guidance tightening expectations around documentation and scope, the brands treating residual solvents as optional are accumulating real regulatory exposure.

Here’s a grounded look at what the standard actually requires, where manufacturers most commonly fall short, and how to build a defensible testing program without testing everything indiscriminately.

What Residual Solvents Are and Why They’re in Your Ingredients

Residual solvents are organic volatile chemicals used during the manufacture or purification of pharmaceutical and supplement ingredients that aren’t completely removed in final processing. They’re not intentional additives. They’re process artifacts — the chemical leftovers of extraction, concentration, or synthesis steps.

For raw material and ingredient-level verification, Ayah Labs specializes in contract testing and supplier qualification.

The most common entry point in dietary supplements is botanical extraction. Manufacturers producing fish oil concentrates, plant-based extracts, and fat-soluble vitamin preparations routinely use organic solvents to isolate or concentrate the target compounds. Hexane is widely used to extract omega-3 fatty acids from fish tissue and to defat botanical materials before further processing. Ethyl acetate appears in green tea extract manufacturing. Acetone shows up in certain recrystallization steps for amino acids and standardized botanical compounds.

ICH guideline Q3C — which USP <467> is harmonized with — organizes residual solvents into three classes based on toxicological risk:

• Class 1 solvents are known or suspected human carcinogens and genotoxins. They should be avoided entirely in manufacturing. Benzene is capped at 2 ppm. Carbon tetrachloride at 4 ppm. Encountering Class 1 solvents in finished supplement ingredients isn’t a paperwork problem — it’s an immediate supply chain failure that warrants lot rejection and supplier audit.

• Class 2 solvents have significant but non-carcinogenic toxicity and carry defined permitted daily exposure (PDE) limits. Hexane’s PDE is 2.9 mg/day, which translates to a concentration limit of 290 ppm in the finished ingredient assuming a typical daily dose. Methanol is permitted up to 3,000 ppm. Acetonitrile at 410 ppm. These limits aren’t conservative estimates — they’re derived from animal toxicology studies with uncertainty factors applied.

• Class 3 solvents are considered low-risk and are permitted up to 5,000 ppm without toxicological justification. Ethanol, ethyl acetate, acetone, and acetic acid fall here. “Low-risk” doesn’t mean undetectable is optional — it means the bar for acceptable levels is higher.

The practical problem for supplement brands is Class 2, specifically hexane. We’ve tested incoming botanical raw materials — fish oil concentrates, saw palmetto extract, evening primrose oil — and found hexane at levels ranging from 400 ppm to over 1,500 ppm. Both of those readings exceed the 290 ppm limit. Both came with supplier COAs that contained no residual solvent data whatsoever.

What USP <467> Actually Requires — Option 1 vs. Option 2

USP <467> is the compendial method for residual solvent analysis. For pharmaceutical products it’s mandatory. For dietary supplements, FDA’s cGMP regulations under 21 CFR Part 111 don’t explicitly require USP <467> compliance by name — but the standard is the accepted scientific basis for establishing what “residually pure” means, and FDA reviewers know it well.

The chapter offers two testing approaches:

Option 1 is a universal screen. Using GC-headspace (GC-HS) with two separate column chemistries, you test the sample against all Class 1 and Class 2 solvents simultaneously. If nothing is detected above reporting thresholds, you have a clean result and you’re done. This approach is appropriate when you don’t have documented knowledge of which solvents were used in manufacturing — which describes most imported botanical raw materials and any ingredient sourced from a supplier who won’t provide process documentation.

Option 2 is targeted testing. If you have a supplier-provided declaration specifying which solvents were used (and only those), you test only for the declared solvents. It’s faster and less expensive per analysis. But it requires documentation quality that many supplement supply chains genuinely don’t have. A COA that says “manufactured using food-grade ethanol” is not a sufficient declaration for Option 2 purposes if you can’t verify how the supplier defines “food-grade” and whether ethanol was the only solvent involved.

The analytical technique underlying both options is gas chromatography with headspace sampling (GC-HS). The sample is dissolved in a compatible solvent, sealed in a vial, and heated until volatile compounds equilibrate into the headspace vapor above the liquid. That vapor is injected directly into the GC column, separating compounds by their volatility and polarity. The method achieves detection limits in the low parts-per-million range for most Class 1 and Class 2 solvents, and GC-MS confirmation can push specificity even further when needed.

One update in the revised USP <467> chapter that catches manufacturers off guard: the limits apply at the ingredient level, not as a daily dose calculation alone. Some brands have tried to argue that even if hexane is at 600 ppm in a fish oil ingredient, the low dose size means total daily hexane intake stays under 2.9 mg. USP’s current language makes clear that concentration-based limits at the ingredient level must be met independently — you can’t dilute your way into compliance by pointing at the capsule fill weight.

The FDA Enforcement Reality Under 21 CFR Part 111 and Section 402

Here’s the regulatory nuance worth understanding clearly: 21 CFR Part 111 — FDA’s cGMP standard for dietary supplements — does not include a specific mandate to run USP <467> residual solvent tests. It does, however, require under §111.70 that manufacturers establish written specifications for the purity and composition of every dietary ingredient and component, with limits on contaminants that may adulterate the supplement.

Under 21 CFR Section 402, a dietary supplement is adulterated if it contains any poisonous or deleterious substance that may render it injurious to health under the conditions of use. FDA doesn’t need a residual solvent-specific regulation to take action under that provision. A supplement ingredient with 900 ppm hexane — a neurotoxin at sufficient doses — is not going to fare well under that standard in a court or administrative proceeding.

What we’ve seen directionally in FDA’s enforcement activity through 2024 and into 2025 is increased attention to foreign ingredient supplier practices, particularly from botanical extract manufacturers in China and India, which collectively supply a substantial share of the U.S. supplement raw material market. Import alerts for adulteration have cited ingredient purity issues with increasing specificity. The documentation burden on supplement brands for incoming ingredient qualification has quietly increased even without formal regulatory revision.

If an FDA investigator arrives at your facility requesting residual solvent specifications and supporting test records for your botanical ingredients and you have neither, that’s a 483 observation waiting to happen — regardless of whether any specific numerical limit was violated. The expectation of documented purity controls is embedded in Part 111. Residual solvents fall squarely within it.

Where Most Supplement Brands Get This Wrong

The most common mistake is testing only at the finished product stage. By the time a suspect botanical extract has been blended, encapsulated, and bottled, testing the finished product identifies the failure — but you’ve already consumed the lot in production. Raw material testing, done on incoming lots before they enter your manufacturing queue, is where you catch non-conformances in time to act.

The second mistake is one-time supplier qualification without ongoing verification. A supplier who passed your initial qualification test two years ago may have since changed their extraction solvent, outsourced part of their processing, or switched contract manufacturers. Manufacturing practices drift. Annual verification testing on high-risk ingredient categories — botanical extracts, fatty acid concentrates, fat-soluble vitamins produced by solvent-assisted synthesis — is the minimum defensible frequency. For new suppliers or new ingredient lots from existing suppliers, test before first use.

The third gap is in documentation. If you receive a COA from a supplier that lists identity, potency, heavy metals, and microbiological data but contains no residual solvent information, that COA is incomplete for ingredients where solvent use is a plausible part of the manufacturing process. “Not tested” is not the same as “not present.” FDA’s expectation under 21 CFR Part 111 is that your specifications reflect the actual risk profile of your ingredients — and for hexane-extracted botanicals, the risk profile includes solvents.

Building a Practical Residual Solvent Testing Program

A sound program doesn’t require testing every ingredient for every solvent at every lot. It requires testing intelligently, based on process risk.

Start by categorizing your raw material inventory. Any botanical extract, fish or algal oil concentrate, fat-soluble vitamin, or ingredient sourced from a manufacturer who cannot provide process documentation is high-risk — meaning the extraction method and solvent history are unknown or unverified. These should receive Option 1 full screening at minimum annually and on every new lot from a new supplier.

Ingredients manufactured by aqueous or enzymatic processes, fermentation-derived ingredients, or synthetically produced compounds where the synthesis route is documented and doesn’t involve Class 1 or Class 2 solvents can be managed with targeted testing or periodic verification on a risk-assessed basis.

For established suppliers with strong testing histories and batch-level COAs from ISO 17025-accredited laboratories that include explicit residual solvent data, a skip-lot or annual verification approach is defensible — provided you have the documentation to support it. “We trust this supplier” is not documentation. Test records, supplier qualification audits, and specification sheets are documentation.

At Qalitex, residual solvent screening under USP <467> Option 1 via GC-headspace is a standard part of our botanical ingredient testing panel. Turnaround is typically 5–7 business days, and results cover the complete Class 1 and Class 2 solvent profile — not just what a supplier chose to disclose on their COA.

The practical first step: pull your top botanical and oil-based raw material suppliers and request their most recent residual solvent test data — specifically, the analytical method used and the list of solvents tested. If they can’t provide it, or the COA shows only ethanol with nothing else listed, schedule verification testing before your next production run. It’s not excessive caution. It’s the baseline that a defensible quality program looks like in 2026.